Acamprosate and naltrexone work at opposite ends of the addiction cycle, which is why the choice between them is mechanistic rather than arbitrary. Acamprosate (666 mg three times daily) stabilizes the glutamate system during withdrawal and helps maintain abstinence in already-detoxified patients. Naltrexone (50 mg daily, or 380 mg as a monthly injection) blocks opioid receptors and blunts the reward that drives heavy drinking. Head-to-head trials show them roughly comparable on continuous abstinence, but naltrexone has stronger evidence for reducing heavy-drinking days. Per the 2020 American Psychiatric Association practice guideline, both are first-line medications for alcohol use disorder.
The two mechanisms, one level deeper
Alcohol dependence reshapes two separate signaling systems, and each drug targets one. Understanding this split explains nearly everything about how the medications differ in practice.
Acamprosate targets the glutamate system. Chronic alcohol exposure upregulates NMDA receptors and sensitizes the brain to glutamate. When drinking stops, that upregulated system fires without alcohol's dampening effect, producing the hyperexcitability of early withdrawal: anxiety, insomnia, and dysphoria. Acamprosate is an acetylated homotaurine that appears to modulate NMDA receptor activity and restore the glutamate-GABA balance. Its clinical identity is a withdrawal-normalizing drug. It works best in patients who have already stopped drinking and need help staying stopped. In plain terms: acamprosate treats the craving and distress that come from a brain that has adapted to alcohol.
Naltrexone targets the opioid system. Alcohol triggers endogenous opioid release, which feeds the dopamine reward signal that reinforces drinking. Naltrexone is a competitive antagonist at mu-opioid receptors; by blocking that link, it removes much of alcohol's reward. The clinical identity here is a reward-blunting drug. It reduces the pleasure and reinforcement of a drink, which lowers heavy drinking even in patients who are not fully abstinent. Some prescribers use it in a targeted way, taken about an hour before anticipated high-risk drinking situations, an approach with supporting trial data.
The practical consequence: acamprosate is usually paired with a goal of complete abstinence after detoxification, while naltrexone can be used with either an abstinence goal or a reduction goal. Neither is a substitute for addressing withdrawal itself; both are maintenance medications begun after acute withdrawal is managed.
Quantified comparison: what the trial data actually show
The best-known head-to-head is the COMBINE study (Anton et al., 2006), which randomized 1,383 patients and tested medications with and without a combined behavioral intervention. It found naltrexone and acamprosate each modestly better than placebo on the primary drinking outcome, but not better than each other. A widely cited network meta-analysis (Jonas et al., 2014, JAMA) pooled 122 trials and found naltrexone reduced heavy drinking (number needed to treat of about 12 for return to any drinking and about 20 for heavy drinking) and acamprosate reduced the risk of any drinking (NNT about 12). The numbers are close, which is the honest headline: neither drug dominates.
| Feature | Acamprosate | Naltrexone (oral / injection) |
|---|---|---|
| Target system | Glutamate (NMDA modulation) | Opioid (mu-receptor antagonist) |
| Typical dose | 666 mg three times daily | 50 mg daily / 380 mg monthly |
| Dosing burden | Three times daily | Once daily or monthly |
| Best evidence | Maintaining abstinence | Reducing heavy drinking days |
| Liver caution | No dose adjustment for mild-moderate hepatic impairment | Hepatotoxicity risk at high doses; check liver enzymes |
| Opioid interaction | None | Blocks opioid analgesics; precipitates withdrawal |
| Renal caution | Requires dose reduction if CrCl 30-50 mL/min; contraindicated below 30 | No renal adjustment needed |
| Common side effects | Diarrhea, nausea, headache | Nausea, headache, fatigue, dizziness |
| Cost (US, approximate) | USD 30-100 per month | USD 40-150 per month oral; injection higher |
The cost figures are approximate cash prices and vary widely by insurance, so treat them as a rough ordering rather than fixed values.
Timeline: how each drug behaves over weeks
Neither medication works on day one, and expecting instant effects is a common reason patients stop early. The time course below reflects typical clinical experience and label information.
| Timepoint | Acamprosate | Naltrexone |
|---|---|---|
| Day 1-3 | Started after detox; steady-state not yet reached | Started after detox and opioid-free period (7-10 days) |
| Week 1-2 | Craving and withdrawal distress begin to ease | Reward-blunting effect present within days |
| Week 2-4 | Full effect typically established | Full blockade established; liver enzymes checked at baseline |
| Month 1-3 | Continued abstinence support; reassess adherence | Reassess drinking reduction; consider injection if adherence poor |
| Month 3-6 | Continue if benefit; reassess at 3-6 months | Continue if benefit; monitor liver |
| Month 6-12 | Many patients continue long-term | Continue; injection avoids daily pill burden |
| Discontinuation | No withdrawal; taper not required | No withdrawal; opioid analgesia restored after a few days |
The key reconciliation: acamprosate's benefit builds over the first two to four weeks, whereas naltrexone's reward-blocking effect appears within days of reaching steady state. These timelines are not directly comparable because they measure different things.
Edge cases and non-obvious details
Several clinical nuances are routinely missed in shorter comparisons. First, naltrexone and opioid painkillers cannot coexist. A patient on naltrexone who needs surgery or acute pain control faces a genuine problem: the drug blocks opioid analgesia, and it can precipitate withdrawal in anyone still taking opioids. This is a hard contraindication, not a preference.
Second, acamprosate's three-times-daily schedule is a real adherence problem. Trials show adherence is a leading predictor of outcome for both drugs, and a drug taken inconsistently underperforms regardless of mechanism. For patients who struggle with pills, the monthly naltrexone injection sidesteps the issue.
Third, the liver caution cuts both ways. Naltrexone carries a hepatotoxicity warning at higher doses, and baseline liver enzymes are standard practice. Acamprosate is largely renally cleared and needs dose reduction when creatinine clearance falls to 30-50 mL/min, with contraindication below 30 mL/min. A patient with advanced kidney disease is a poor candidate for acamprosate.
Fourth, a counterintuitive point: the drugs appear to work better together with behavioral support than alone, and COMBINE found that medication plus a structured behavioral program outperformed either alone in some analyses. The medication is not a standalone cure.
Fifth, neither drug treats withdrawal. Benzodiazepines manage acute withdrawal; acamprosate and naltrexone are maintenance tools started afterward.
Common misconceptions corrected
A frequent misconception is that naltrexone makes drinking impossible. It does not. A determined patient can drink through the blockade; the drug reduces reward, not access. Another is that acamprosate only works for people who never drink again. Trial data show benefit on abstinence maintenance, but it is not a guarantee, and relapse is common.
A third misconception is that the two drugs are interchangeable. They target different systems, have different dosing, and differ in hepatic and renal cautions. Switching is reasonable if one fails or is poorly tolerated, but the choice should be deliberate.
Finally, a professional caveat: many of the positive trial results come from patients who received structured counseling and monitoring. Real-world outcomes depend heavily on adherence and follow-up. The medication is a tool inside a treatment program, not a replacement for one.
What to actually do
- Get evaluated for detoxification first if you have been drinking heavily; withdrawal can be medically dangerous.
- Ask your clinician to review liver and kidney function before starting either drug.
- Tell your prescriber about any opioid use, including pain medication, before naltrexone.
- If adherence is unreliable, ask about the monthly naltrexone injection.
- Pair medication with counseling or a structured program; the evidence supports the combination.
- Reassess at three to six months with your clinician rather than stopping silently.
Red flags warranting immediate medical contact:
- Signs of severe alcohol withdrawal (tremor, confusion, seizures, rapid heart rate).
- New abdominal pain or jaundice while on naltrexone.
- Severe diarrhea or dehydration on acamprosate.
- Any opioid use while taking naltrexone.
- Worsening mood or suicidal thoughts.
Limitations of the evidence
The honest limitation is that head-to-head data are limited and often short-term. COMBINE followed patients for 16 weeks; longer-term comparative data are sparse. Most trials enrolled treatment-seeking adults, so generalizability to other groups is uncertain. Effect sizes are modest, and neither drug is a cure. Individual response varies, and the best choice often emerges through a trial of one medication with close monitoring. The comparison here reflects established trial evidence, not a guarantee of individual outcome.